2010 Announcements

Appendix 3B

Amendment to Appendix 3Y

Appendix 3Y

Letter from the CEO

Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that it had completed a consolidation of the company’s shares on a one-for-ten basis approved at the 2010 Annual General Meeting of shareholders on November 11. Holding statements have been dispatched to shareholders advising them of their holdings. Further details can be found in the attached PDF.

Appendix 3B

Fourth regulator recognises drug’s potential to treat two rare diseases Clinuvel Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that the Therapeutic Goods Administration (TGA), Australia’s regulatory body for drugs and medical devices, has granted Clinuvel’s first-in-class drug SCENESSE® (afamelanotide) orphan drug designation (ODD) for erythropoietic porphyrias (EPP and CEP), two rare genetic diseases causing skin intolerance to light. The TGA is the fourth global regulator to grant SCENESSE® ODD status after similar recognition from the European Medicines Agency, SwissMedic and the US FDA in 2008. The Australian ODD provides Clinuvel with a waiver of all registration fees…

Approval to Consolidate Share Capital on 10:1 ratio

Results of Meeting